Cerebral malaria, a reversible encephalopathy affecting young children, is a medical emergency requiring urgent clinical assessment and treatment. We performed a whole-transcriptomic analysis of blood samples from Malian children with cerebral or uncomplicated malaria. We focused on transcripts from pathways for which dysfunction has been associated with neurodegenerative disorders. We found that SNCA, SIAH2, UBB, HSPA1A, TUBB2A, and PINK1 were upregulated (fold-increases, ≥2.6), whereas UBD and PSMC5 were downregulated (fold-decreases, ≤4.39) in children with cerebral malaria, compared with those with uncomplicated malaria. These findings provide the first evidence for pathogenic mechanisms common to human cerebral malaria and neurodegenerative disorders.
clinical outcomes. Analyses of differential gene expression constitute a powerful approach for identifying suitable biological indicators for predicting the eventual outcome of P. falciparum infection, making it possible to provide appropriate treatment more rapidly. Recent complementary DNA microarray studies have shown significant differences between the gene expression profiles of CM-resistant and CM-susceptible mice [1] . In humans, transcriptomic analyses of RNA extracted from the peripheral blood mononuclear cells (PBMCs) of malarial patients infected with P. falciparum revealed that changes in the expression of human innate immune pathway genes were correlated with the severity of malaria [2] . Whole-blood transcriptomic analyses have also provided insight into pathogenesis and have been used to identify biomarkers of neurodegenerative and psychiatric disorders [3] or of other infectious diseases, such as leprosy.
The aim of this study was to use blood-based gene expression profiles to identify biological pathways and molecules potentially reflecting the pathological mechanisms of CM. We used a gene selection strategy combining expression profiling and pathway analysis to focus on genes displaying changes in expression also known to be associated with neurological disorders. We show here, for the first time, that CM and neurodegenerative disorders have pathogenic mechanisms in common.
METHODS
This study was approved by the local ethics committees of the Faculty of Medicine, Pharmacy, and Odonto-Stomatology of the University of Bamako and by French ethics committees, including those of INSERM, the Comité de Protection des Personnes (protocol 212 CO2), the Ministère de l'Enseignement Supérieur et de la Recherche (protocol DC-2011-1426), and the Commission Nationale de l'Informatique et des Libertés (protocol 1564177). All experimental methods were performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all parents.
Patients
CM was defined according to World Health Organization criteria as a state of unarousable coma with a Blantyre coma scale score of <2, a hematocrit of >16%, and parasitemia with asexual stages of P. falciparum. Meningitis was ruled out by lumbar puncture. Subjects with uncomplicated malaria (UM) had a thick blood film positive for P. falciparum, a Blantyre coma scale score of 5, and a hematocrit of >26%. The children with UM had never developed CM. Malian children were recruited through the Pediatrics Department of Gabriel Toure Hospital in Bamako, as part of a larger prospective field study.
In this study, we analyzed gene expression in 13 patients with CM (male to female ratio, 7:6; mean age [±SD], 6.2 ± 3.8 years)
B R I E F R E P O R T and 12 patients with UM matched for age and sex (male to female ratio, 6:6; mean age [±SD], 6.5 ± 3.6 years). Blood samples were collected before the treatment of the children.
RNA Extraction
A peripheral blood sample was collected from each participant, and peripheral blood mononuclear cells (PBMCs) were isolated within 1 hour after sample collection. Total RNA was extracted with TRIzol reagent (Life Technologies) according to the manufacturer's instructions but with an additional purification step performed with the RNA Clean and Concentrator kit (Zymo Research). The quality of total RNA was assessed with an RNA LabChip (Agilent 2100 Bioanalyzer, Agilent). Only samples with an RNA integrity number of >8 were used for further analysis.
Whole-Transcriptome Analysis
The samples of high-quality RNA were marked with Cy3 fluorescent dye, and then they were hybridized using the SurePrint G3 Human Gene Expression 8 × 60K microarray kit, version 1 (Agilent), according to the manufacturer's instructions. The slides were composed of 8 high-definition 60-mer oligomicroarrays. Each microarray contained about 22 700 genes based on RefSeq and 7419 large intergenic noncoding RNAs. Fold-changes and P values were calculated for each gene, using Genespring Software (Agilent). The moderated t test and the Benjamini-Hochberg correction were used to obtain the P value. Pathway analysis was also performed with Genespring Software.
Validation of Gene Expression Data by Quantitative Real-Time Polymerase

Chain Reaction (PCR) Analysis
We reverse-transcribed 400 ng of total RNA to generate complementary DNA. The expression of selected genes was analyzed by TaqMan PCR, on an ABI 79000 real-time PCR thermocycler (Life Technologies), according to the manufacturer's instructions. The data were normalized with 2 housekeeping genes (RPLP0 and GAPDH). Data were analyzed by the ΔΔCt method (2 -ΔΔCt ), with Thermo-Fisher software (cloud).
RESULTS
We characterized the biological pathways dysregulated during CM by analyzing the transcriptomes of 7 children with CM and 8 children with UM who were selected at random. In total, 2900 probe sequences differed significantly between the CM and UM groups, with an absolute fold-change of >1.1 and a P value of <.05, even after Benjamini-Hochberg correction (Table 1) . In total, 436 probe sequences were identified as differentially expressed, yielding an absolute fold-change of >3 (Table 1) : 403 of these sequences were upregulated and 33 downregulated in children with CM. GeneSpring pathway analysis revealed that a number of different Wiki biological pathways were significantly associated with the disease (Table 2) . Remarkably, several genes from pathways associated with neurodegenerative disorders were substantially overexpressed or underexpressed in patients with CM relative to those with UM ( Table 2 ). In particular, 18 genes from the parkin-ubiquitin proteasomal system, 14 from the proteasome degradation pathway, and 6 from the Parkinson disease pathway were found to be differentially expressed between the 2 groups. Six genes from these 3 pathways were significantly more strongly expressed in children with CM than in those with UM, with fold-increases of >2: SNCA, SIAH2, UBB, HSPA1A, TUBB2A, and PINK1 (Table 3) . Four genes, UBD, UBE1L, PSMC5, and PSMD5, were downregulated in children with CM, with fold-decreases of ≤4.39 (Table 3) .
We investigated whether the changes in expression observed on microarray analysis for these 10 selected genes could be confirmed in a larger sample set of 13 children with CM and 12 with UM. Real-time PCR validation was performed in duplicate and confirmed the significant difference in expression levels for 8 genes. The relative expression levels (2 -ΔCT ) for these genes are The WikiPathways in which the genes were known to be involved are listed. We show only the pathways containing at least 3 dysregulated genes and known to be involved in neurodegenerative disorders or identified in gene expression analysis in a mouse model of malaria.
presented in Figure 1 . The difference in expression between subjects with CM and those with UM, expressed as a fold-increase, was 3.2 for SNCA (P = .026), 3.1 for SIAH2 (P = .001), 2.6 for UBB (P = .004), 2.7 for HSPA1A (P = .013), 3.2 for TUBB2A (P = .009), and 3.2 for PINK1 (P = .001), whereas for UBD and PSMC5, we obtained a fold-decrease of 6 (P = .001) and 1.5 (P = .01), respectively. We then analyzed the relationship between the expression levels of these genes in patients with CM and those with UM. We found significant positive correlations between expression levels for each pair-wise comparison between UBB, SIAH2, SNCA, TUBB2A, and PINK1 (P < .01; Pearson correlation, >0.8). We found significant negative correlations between expression levels in children for UBD and PINK1 (P = .01; Pearson correlation, -0.646) and for UBD and SIAH2, SNCA, TUBB2A, and UBB (P < .05; Pearson correlation, less than -0.4).
Discussion
In this study, we identified human genes and pathways involved in CM, suggesting possible targets for drug development. The key findings of this study are (1) the efficacy of this approach for identifying changes in the levels in human peripheral blood of transcripts involved in both CM and neurological disorders, Parkinson disease, and Alzheimer disease; (2) the overlap between the pathways dysregulated in both the human and mouse model of CM, such as glycolysis/gluconeogenesis, tryptophan metabolism, immune responses, and brain function [1] ; and (3) the confirmation that the molecular profiling of PBMCs can reflect physiological and pathological events in the brain, as previously suggested by Mohr et al [4] .
We focused here on genes and pathways that have been clearly implicated in neurological disorders: the interconnected parkin, Parkinson, and proteasome pathways, in particular. These pathways were considered to be of particular interest because they had never before been studied in human malaria, unlike immune response pathways [2, 5] . We showed that SNCA, SIAH2, HSPA1A, TUBB2A, PINK1, and UBB were expressed significantly more strongly in patients with CM than in patients with UM, whereas UBD and PSMC5 from the proteasome degradation pathway were expressed less strongly. Our findings suggest that transcriptomic analyses of peripheral blood can provide important insights into pathogenic mechanisms affecting the brain. These findings are entirely consistent with those of Liew et al [6] , indicating significant similarities in gene expression between the blood and brain (>80%) and showing that the profiling of gene expression in the blood could be used for diagnostic and prognostic purposes.
SNCA, which encodes α-synuclein, a protein expressed predominantly in the brain, has been identified as the major causal gene in several neurodegenerative disorders. There is growing evidence to suggest that the overproduction and aggregation of this protein lead to brain dysfunction that is sufficient to cause disease [7] . We found that SNCA was overexpressed in children with CM, suggesting a possible deleterious role of this gene in this disease. Another gene from the same pathway, SIAH2, was also overexpressed in children with CM. This gene encodes an E3 ubiquitin-conjugating enzyme that plays a critical role in the hypoxia response [8] , which is frequently observed in patients with CM. Under hypoxia, SIAH2 messenger RNA levels increase and the encoded protein interacts with α-synuclein, promoting its aggregation, which is toxic. The formation of these aggregates is prevented by the suppression of endogenous SIAH2 expression. PTEN-induced kinase 1 (PINK1) is a mitochondrial kinase that is strongly expressed in the brain and promotes cell survival, particularly under conditions of oxidative stress. It accumulates on the surface of defective mitochondria and recruits parkin, thereby promoting the selective degradation of dysfunctional mitochondria. Abnormal PINK1 expression may be a causal factor in the development of mitochondrial dysfunction leading to neurodegenerative and neuroinflammatory disorders [9] . Despite its demonstrated protective effects, PINK1 has been shown to be present at abnormally high levels in the brains of individuals with Alzheimer disease or multiple sclerosis [10] , as observed in the blood of children with CM. TUBB2A, which encodes β-tubulin, was also overexpressed during CM. Mutations of this gene cause infantile-onset epilepsy and are associated with impaired brain development in humans, but the underlying pathogenic mechanism is unknown [11] . Molecular chaperones and the ubiquitin proteasome system are the first and second lines of defense against protein misfolding and aggregation. HSP-70, encoded by HSPA1A, is a chaperone protein that plays an important role in the refolding of misfolded proteins and the targeting of proteins for proteasomal degradation. A loss of Hsp70 activity has been associated with neurodegeneration and the formation of amyloid deposits of α-synuclein in Parkinson disease. However, the ability of HSP-70 to inhibit the aggregation of α-synuclein depends on factors such as nucleotide binding and the presence of the Hip cochaperone. In the presence of ATP (or ADP), Hsp70 overexpression may reduce α-synuclein toxicity but without preventing the highly cytotoxic accumulation of amyloid aggregates in tissue [12] . We found that HSPA1A was overexpressed in children with CM, as in patients with epilepsy, in whom HSP-70 levels are correlated with the duration and intensity of seizures, suggesting that this protein may be a marker of seizure-related brain injury [13] . Inflammation and oxidative stress, characteristic features of CM, may account for the increase in HSPA1A transcript levels in this disease and may reflect the severity of the injury. Nevertheless, further studies are required to determine whether HSP-70 is a cause or a consequence in the pathogenesis of CM. The ubiquitin proteasome system is an intracellular protein degradation system that plays an important role in maintaining intracellular homeostasis [14, 15] . The impairment of this system leads to protein accumulation, resulting in neurodegenerative diseases, such as Alzheimer disease and Parkinson disease. The upregulation of UBB and the downregulation of UBD and PSMC5 in children with CM suggest that the ubiquitin proteasome system is disturbed. Exogenous stress, mitochondrial alterations, and α -synuclein overexpression may also promote disruption of the ubiquitin proteasome system, with potentially protein aggregates.
In conclusion, our results suggest that CM has pathogenic mechanisms in common with other brain disorders involving protein aggregation. They also show that transcriptomic analysis of PBMCs is an efficient method for investigating changes in the brain. The identification of new molecules involved in CM pathogenesis could improve diagnostic capabilities or facilitate the development of new treatments. 
